1.63
+0.12(+7.95%)
Currency In USD
| Previous Close | 1.51 |
| Open | 1.53 |
| Day High | 1.66 |
| Day Low | 1.52 |
| 52-Week High | 2.14 |
| 52-Week Low | 0.92 |
| Volume | 2.22M |
| Average Volume | 1.86M |
| Market Cap | 626.84M |
| PE | -4.18 |
| EPS | -0.39 |
| Moving Average 50 Days | 1.36 |
| Moving Average 200 Days | 1.26 |
| Change | 0.12 |
If you invested $1000 in Standard BioTools Inc. (LAB) 10 years ago, it would be worth $190.2 as of January 14, 2026 at a share price of $1.63. Whereas If you bought $1000 worth of Standard BioTools Inc. (LAB) shares 5 years ago, it would be worth $273.03 as of January 14, 2026 at a share price of $1.63.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations of approximately $85 millionBOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“St
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025
GlobeNewswire Inc.
Oct 21, 2025 11:00 AM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish third quarter 2025 financial results on Tuesday, November 4, 2025, after U.S. market close. About Standard BioT
Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study
GlobeNewswire Inc.
Aug 06, 2025 11:00 AM GMT
PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan’s strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN